Ixekizumab is available both as an autoinjector and prefilled syringe for subcutaneous (SC) administration.1

Ixekizumab is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in SC injection technique using the autoinjector or prefilled syringe.1

Each ixekizumab injection is to be administered

• at a different anatomic location (such as upper arms, thighs, or any quadrant of the abdomen) than the previous injection, and
• not into areas where the skin is tender, bruised, erythematous, indurated, or affected by psoriasis.1

Administration into the upper outer arm may be performed by a caregiver or healthcare provider.1

Before injection, remove the autoinjector or prefilled syringe from the refrigerator and allow ixekizumab to reach room temperature (30 minutes) without removing the needle cap.1

Inspect ixekizumab visually for particulate matter and discoloration prior to administration. The ixekizumab solution should appear clear and colorless to slightly yellow. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).1

Ixekizumab does not contain preservatives, therefore discard any unused product remaining in the autoinjector or prefilled syringe.1

Instruct patients using the autoinjector or prefilled syringe to inject the full amount (1 mL), which provides 80 mg of ixekizumab, according to the directions provided in the instructions for use.

Each autoinjector and prefilled syringe contain a single-dose (80 mg/mL) solution of ixekizumab.1

TALTZ® (ixekizumab) injection, for subcutaneous administration, Lilly